Clinical trials: MAB
Duchenne Muscular Dystrophy
Trial of Pamrevlumab (FG-3019), in Non-Ambulatory Participants With Duchenne Muscular Dystrophy (DMD)
This is a Phase 2, open-label, single arm trial of pamrevlumab (FG-3019) to estimate pamrevlumab's safety and efficacy in non-ambulatory participants with DMD.
- Trial name
- MISSION (NCT02606136)
- Testing
- Pamrevlumab
- Where
- 10 sites in United States
- Volunteers
- 21 people
- Sponsor
- Kyntra Bio
Leukemia, Multiple Myeloma and Plasma Cell Neoplasm
Monoclonal Antibody Therapy or Biological Therapy in Treating Patients With Chronic Lymphocytic Leukemia or Multiple Myeloma in Remission After Chemotherapy
RATIONALE: Monoclonal antibodies such as rituximab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00004040
- Testing
- recombinant interferon alfa, rituximab
- Where
- 3 sites in United States
- Sponsor
- Hoag Memorial Hospital Presbyterian
Graft Rejection, Kidney Disease
Effectiveness of the Investigational Drug Campath-1H in Preventing Rejection of Transplanted Kidneys
This protocol will test a humanized monoclonal antibody known as Campath-1H for its ability to induce a state of permanent allograft acceptance, or tolerance, when administered in combination with a brief course of the…
- Trial name
- NCT00001984
- Testing
- Alemtuzumab and DSG
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Systemic Lupus Erythematosus
A Study to Investigate Pharmacokinetics, Pharmacodynamics, and Safety of Subcutaneous Anifrolumab in Pediatric Participants 5 to < 18 Years of Age With Systemic Lupus Erythematosus
The purpose of this study is to characterize the pharmacokinetics (PK), pharmacodynamics (PD), and safety of subcutaneous (SC) anifrolumab in pediatric participants with moderate to severe systemic lupus erythematosus (SLE) while…
- Trial name
- NCT07630714
- Testing
- Anifrolumab + APFS
- Where
- 39 sites in Australia, Belgium and 8 more
- Volunteers
- 24 people
- Sponsor
- AstraZeneca
Hepatitis
Severe Hepatitis Intervention With Emapalumab for Liver Disease
The goal of this study is to see whether a medicine called emapalumab, a monoclonal antibody, is safe and works well for patients aged 1 year and older who have indeterminate severe hepatitis with T-cell activation and have not…
- Trial name
- SHIELD (NCT07744919)
- Testing
- Emapalumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Children's Healthcare of Atlanta